OncoMed to Present Data on Anti-Cancer Stem Cell Candidates

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OncoMed to Present Data on Anti-Cancer Stem Cell Candidates at the American Association of Cancer Research Meeting

REDWOOD CITY, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq: OMED ), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it will provide an extensive update on its anti-cancer stem cell pipeline at the upcoming American Association of Cancer Research (AACR) meeting to be held April 5-9, 2014 in at the San Diego Convention Center in San Diego, CA.

"The nine presentations at the upcoming AACR meeting highlight the strength our research team's ongoing efforts to constantly advance our knowledge of cancer stem cell pathways, predictive biomarkers and anti-tumor activity for our growing pipeline of candidates," said Paul J. Hastings, Chairman and Chief Executive Officer of OncoMed. "These data add to the increasing body of information for OncoMed's clinical-stage candidates and provide results from studies of OncoMed's most advanced preclinical candidates, a bispecific antibody that blocks DLL4 and VEGF signaling and an antibody that targets the RSPO-LGR cancer stem cell pathway." 

The list of abstracts and timing of the presentations by OncoMed scientists is provided below.

Oral Presentation
1. "Using PDX Models for Anticancer Drug Screening" will be presented by Timothy Hoey, PhD, Senior Vice President, Cancer Biology.
Date and time: Saturday, April 5, 2014, 10:45 am – 11:10 am PT
Location: Room 25A-C
Session: Methods Workshop, "Applications of Patient Derived Xenograft Models to Translational Cancer Research"
 
Posters
2. "NOTCH3 expression is predictive of efficacy in pancreas tumor models treated with OMP-59R5, a monoclonal antibody targeting the NOTCH2 and NOTCH3 receptors" (Abstract #910) will be presented by Belinda Cancilla, PhD, Director.
Date and time: Sunday, April 6, 2014, 1:00 pm – 5:00 pm PT
Location: Hall A-E
Poster Section 37: Predictive Biomarkers 1
 
3. "Dual targeting of DLL4 and VEGF signaling by a novel bispecific antibody inhibits tumor growth and reduces cancer stem cell frequency" (Abstract #207) will be presented by Wan-Ching Yen, PhD, Senior Scientist II.
Date and time: Sunday, April 6, 2014, 1:00 pm – 5:00 pm PT
Location: Hall A-E
Poster Section 8: Stem Cell Expansion and Anti-Cancer Stem Cell Targeting
 
4. "Inhibition of R-spondin (RSPO) signaling reduces the growth of multiple human tumors" (Abstract #1764) will be presented by Austin Gurney, PhD, Senior Vice President, Molecular and Cellular Biology. 
Date and time: Monday, April 7, 2014, 8:00 am – 12:00 pm PT
Location: Hall A-E
Poster Section 32: New Targets and Agents 1
 
5. "The combination of gemcitabine/ nab -paclitaxel and anti-DLL4 (demcizumab) produces synergistic growth inhibition, delays tumor recurrence and reduces tumor initiating cells in pancreatic cancer" (Abstract #1898) will be presented by Dr. Hoey. 
Date and time: Monday, April 7, 2014, 8:00 am – 12:00 pm PT
Location: Hall A-E
Poster Section 37: New Diagnostics, Therapeutic Targeting, and Response Assessments
 
6. "Wnt pathway antagonist OMP-54F28 (FZD8-Fc) inhibits tumor growth and reduces tumor-initiating cell frequency in patient-derived hepatocellular carcinoma and ovarian cancer xenograft models" (Abstract #1907) will be presented by Pete Yeung, Associate Scientist.
Date and time: Monday, April 7, 2014, 1:00 pm – 5:00 pm PT 
Location: Hall A-E
Poster Section 1: Cancer Stem Cell Phenotype and Function 1
 
7. "Predictive biomarker identification for response to vantictumab (OMP-18R5; anti-Frizzled) by mining gene expression data of human breast cancer xenografts" (Abstract #2830) will be presented by Chun Zhang, PhD, Sr. Scientist II. 
Date and time: Monday, April 7, 1:00 pm – 5:00 pm PT
Location: Hall A-E
Poster Section 37: Predictive Biomarkers 2 
 
8. "OMP-59R5 (Anti-Notch2/3) inhibits tumor growth and reduces cancer stem cell frequency in patient derived SCLC xenografts" (Abstract #3048) will be presented by Marcus Fischer, Associate Scientist.
Date and time: Tuesday, April 8, 2014, 8:00 am – 12:00 pm PT
Location: Hall A-E
Poster Section 4: Cancer Stem Cell Phenotype and Function 2 
 
9. "Enhanced anti-tumor effect of WNT pathway antagonists in combination with taxanes" (Abstract #4547) will be presented by Dr. Yen.
Date and time: Tuesday, April 8, 2014, 1:00 pm – 5:00 pm PT
Location: Hall A-E
Poster Section 31: Cell Cycle Mechanisms of Anticancer Drug Action

About Cancer Stem Cells

Cancer stem cells, or CSCs, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain properties which include the capacity to divide and give rise to new CSCs via a process called self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. OncoMed's product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. OncoMed believes its product candidates are distinct from the current generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells. OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (Anti- DLL4, OMP-21M18), OMP-59R5 (Anti-Notch2/3), OMP-52M51 (Anti-Notch1), vantictumab (Anti-Fzd7, OMP-18R5), and OMP-54F28 (Fzd8-Fc), which target key cancer stem cell signaling pathways including Notch and Wnt.  OncoMed has two other antibodies in preclinical development, Anti-DLL4/Anti-VEGF bispecific and Anti-RSPO3, with Investigational New Drug filings planned for late 2014 or early 2015.  OncoMed is also pursuing discovery of additional novel anti-CSC product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com .

Investor Contact: OncoMed Pharmaceuticals Shari Annes Investor Relations (650) 888-0902 Media Inquiries: BCC Partners Karen L. Bergman or Michelle Corral (650) 575-1509 or (415) 794-8662 or

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HIZENERGY Sustains Tier 1 Status Amid Tighter Criteria

Updated Category News Views 30

Another Feather in HIZENERGY's Cap In a landscape where credibility can make or break a business, HIZENERGY has once again staked its claim as a powerhouse. Come Q4 2026, and despite a rougher sea to navigate with BloombergNEF’s (BNEF) upgraded Tier 1 criteria, the company held its own. For those unacquainted, securing a place on this lofty list involves some serious...

Continue Reading
EASE Unlocks $9.5M for AI Medical Expansion in Africa

Updated Category News Views 8

Transforming Healthcare in South Africa and Ghana Expanding into uncharted territories often requires a leap of faith, and EASE Holdings has just taken a substantial one. The medical equipment-as-a-service provider has grabbed a hefty $9.5 million in equity from AAFC Group Inc. The goal? To flood South Africa and Ghana with cutting-edge medical imaging and surgical...

Continue Reading
Brigham Nurses Dig In for Strike: Fight for Fairness

Updated Category News Views 118

Strike Looms as Brigham Nurses Demand Fair Treatment Massachusetts is gearing up for its largest open-ended nursing strike in history as Brigham and Women's Hospital nurses prepare to lay down their tools in pursuit of a just contract. This ain't your typical workplace squabble; it's a full-blown battle for patient safety and professional respect. The Core Grievances at...

Continue Reading
Ascletis Showcases Bold Moves in Obesity Drug Arena

Updated Category News Views 0

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...

Continue Reading
Sinopec Unveils Biodiversity Report at COP17

Updated Category News Views 6

Sinopec's First Step on the Global Biodiversity Stage Seems like Sinopec (HKG: 0386) has decided to toss its hat into the biodiversity conservation ring. At COP17 in Armenia, they released their inaugural Global Biodiversity Conservation Report—an event that marks more than just a company selling oil and gas. Now, they're talking wildlife and ecologies. Is that irony,...

Continue Reading
Dutch Bros Pours Holiday Cheer with New Festive Menu

Updated Category News Views 201

New Festive Offerings from Dutch Bros Kicking off the holiday season with a splash of vibrant flavors, Dutch Bros is shaking up the menu with some fresh, festive entries. Two new drink concoctions hit the stage alongside a themed delectable treat, and for those traditionalists, perennial favorites make a triumphant return. Dutch Bros Expands Its Vibrant Lineup It's not...

Continue Reading
Smart Salary Moves for S Corp Owners: Riggs Unpacks Insights

Updated Category News Views 285

Decoding the S Corp Salary Dance How much salary should the savvy owners of S corporations draw? It ain't a simple task or one-size-fits-all deal, folks. David Riggs spills the beans on HelloNation, sharing insights on this complex tango between drawing wages and raking in shareholder distributions. In the end, it’s about playing by the IRS rules—or risking a penalty...

Continue Reading
Afghanistan Claims Hong Kong Sixes in Thrilling Run Chase

Updated Category News Views 216

Afghanistan's Dazzling Triumph Brace ourselves, because what just unfolded in the Hong Kong Sixes 2026 is nothing short of spectacular. Afghanistan's cricket team penned a brand-new chapter in the game's history by overcoming Australia in a pulsating final to capture their maiden Hong Kong Sixes title. Imagine this: chasing a formidable target of 116, they wrapped up the...

Continue Reading
Ensuring Flooring Stability: Acclimation's Key Role

Updated Category News Views 245

Dive into the World of Flooring Acclimation You ever hear about flooring acclimation? Sounds as riveting as watching paint dry, right? But Austin J. Messina from Salem, New Hampshire, is here to tell us it's the secret to flooring that doesn't buckle under pressure—literally. Messina's insights, splashed across the pages of HelloNation, delve deep into the nitty-gritty...

Continue Reading
Chiropractic Insights: Differentiating Piriformis vs. Disc Pain

Updated Category News Views 196

Understanding Pain: Two Paths, One Problem Buttock and leg pain is a real drag, isn't it? We often brush it off as sciatica, but here's a twist: it might not be the usual corporate villain—a herniated disc. Instead, we could be dealing with an underdog called piriformis syndrome. According to Dr. Mitch Quill, D.C., of HelloNation fame, understanding these nuances isn't...

Continue Reading

Top 5 Most Recently Viewed Articles

Yealink Partners with TÜV SÜD for Enhanced Compliance and Growth

Updated Category News Views 208

Yealink Collaborates with TÜV SÜD for Global Compliance Yealink, the leading provider of unified communication and collaboration solutions, has entered into a significant strategic partnership with TÜV SÜD, a globally recognized authority in testing and certification. This alliance marks an important step in enhancing Yealink's commitment to compliance, product...

Continue Reading
Crocs Faces Setbacks as HEYDUDE Sales Decline, Price Target Adjusted

Updated Category News Views 177

Overview of Crocs' Price Target Adjustment Recently, an update from Williams Trading announced a price target reduction for Crocs (NASDAQ: CROX) from $163 to $140, while still keeping a Buy rating on the company’s stock. This adjustment is attributed to various factors, including a revised outlook on the company's financial performance for the upcoming years....

Continue Reading
Good Times Restaurants Prepares for Q4 Financial Results Call

Updated Category News Views 106

Good Times Restaurants Announces Conference Call for Q4 Results Good Times Restaurants Inc. (Nasdaq: GTIM), known for operating Bad Daddy’s Burger Bar and Good Times Burgers & Frozen Custard, is set to host a conference call discussing its fourth quarter and fiscal results. The call is scheduled for December 12, in the evening. Key executives, including CEO Ryan M. Zink...

Continue Reading
Rubicon Organics Achieves Record Growth in Q1 Financial Results

Updated Category News Views 281

Rubicon Organics Reports Impressive Q1 Financial Growth Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) has recently shared its financial results for the first quarter of 2025, marking a pivotal moment in the company's growth trajectory. The firm reported a net revenue of $12.4 million, showcasing a remarkable increase of 39.2% year-over-year. This strong performance...

Continue Reading
Blue Sky Uranium's Roadmap to Feasibility for Ivana Project

Updated Category News Views 154

Blue Sky Uranium's Strategic Roadmap for the Ivana Deposit Blue Sky Uranium Corp. (TSXV: BSK, OTC: BKUCF) has achieved a significant milestone with the completion of a thorough Gap Analysis for the Ivana Uranium-Vanadium Deposit, located in the Amarillo Grande Project. This analysis lays out a structured approach for advancing the project towards feasibility, making it a...

Continue Reading